There is wide variation in all aspects of Active Surveillance (AS) internationally, from patient selection to investigations and follow-up intervals, and a lack of clear evidence on the optimal approach to AS.
Dr Sigrid Carlsson will provide an overview of the state-of-the-science and latest developments in active surveillance for prostate cancer in 2020. The presentation will include reporting on oncologic outcomes for men with Grade Group 1 & Grade Group 2 prostate cancer managed with active surveillance at a tertiary cancer center. Criteria for eligibility, the active surveillance protocol and the safety of the program will be reviewed. Data on conversion to active treatment and risk of prostate cancer metastasis and mortality will be presented.
Dr Sam Merriel will present on the Delphi study, conducted in conjunction with the 2019 APCC, aimed to provide guidance for clinicians from an international panel of prostate cancer experts. This session will summarise the main findings of this study.